NEW YORK (GenomeWeb News) – XDx today said that Highmark, a health insurer that covers around 4.8 million lives in Pennsylvania and West Virginia, is now covering its AlloMap test for beneficiaries of the health plan.
The AlloMap test is a gene expression-based assay used to aid the monitoring of heart transplant rejection. The test measures the expression levels of 20 genes from a blood sample to provide a score that is used by clinicians to help evaluate the risk of transplant rejection.
Brisbane, Calif.-based XDx said that the AlloMap test is now covered for approximately two-thirds of the US heart transplant population. There are roughly 2,100 heart transplants performed each year in the US and around 20,000 living heart transplant recipients, XDx noted.
AlloMap is performed at XDx's CLIA-certified lab. The test was launched in 2005, cleared by the US Food and Drug Administration in 2008 and received the CE Mark in April 2011.